Source: Eur Respir J 2015; 45: 25-29
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Sotgiu Giovanni, Pontali Emanuele, Migliori Giovanni Battista. Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. Eur Respir J 2015; 45: 25-29

Member's Comments

No comment yet.

Related content which might interest you: Halotherapy and Covid-19: an oppinion for a possible future prevention approach Source: Virtual Congress 2021 – COVID – 19: treatments and predictive factors Year: 2021 Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence Source: Eur Respir J 2013; 42: 288-290 Year: 2013 Current approaches to formulate evidence-based recommendations: a case study of WHO drug-resistant tuberculosis treatment guidance Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 The role of inhaled antibiotics in bronchial infection Source: Eur Respir Monogr 2013; 60: 120-126 Year: 2013 HAP/VAP : new guidelines, new approaches Source: International Congress 2018 – Chinese Programme 2018: Part II Year: 2018 Anti-IgE therapy: rationale and clinical evidence Source: Annual Congress 2007 - Changing practice with anti-IgE: patient, physician and payor perspectives Year: 2007 Cleaning agents and asthma: what does the evidence currently tell us about diagnosis and management of these cases? Source: International Congress 2018 – Cleaning agent exposures: are they really harmful to lung health? Year: 2018 Getting approval for new therapeutic medical devices versus drugs: are the differences justified? Source: Eur Respir Rev 2016; 25: 223-226 Year: 2016 Evidence provided by recent meta-analyses on treatment: what is new? Source: Annual Congress 2012 - PG7 TB and MDR-/XDR-TB: what is new in diagnosis, treatment and follow-up (TB PAN-NET) Year: 2012 Clinical trial landscape for M/XDR-TB: current evidence and future perspectives Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis Year: 2019 Efficacy and safety of new drugs for M/XDR-TB: what have we learned from observational studies? Source: International Congress 2019 – Recent developments and future perspectives in the diagnosis and treatment of tuberculosis Year: 2019 Do we have any alternative therapeutic option beyond antibiotics? Source: Postgraduate course 2021: PG7 - Postgraduate course : Emerging infectious diseases and antimicrobial resistance: diagnostics, treatments, vaccines and other preventive and/or therapeutic interventions Year: 2021 Pharmacological options for the treatment of COPD: present and future Source: Annual Congress 2007 - PG6 - COPD: comprehensive clinical assessment and pharmacological and nonpharmacological therapy Year: 2007 Regimens to treat multidrug-resistant tuberculosis: past, present and future perspectives Source: Eur Respir Rev, 28 (152) 190035; 10.1183/16000617.0035-2019 Year: 2019 Other options of prevention - the current state and the future Source: Annual Congress 2003 - Latent tuberculosis infection - preventive approaches Year: 2003 Can we predict tuberculosis cure? What tools are available? Source: Eur Respir J, 52 (5) 1801089; 10.1183/13993003.01089-2018 Year: 2018 TB following targeted and biological therapy: can we predict it? Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020 Clinical case discussion: How clinical trials inform antibiotic stewardship Source: ERS webinar 2022: Clinical case discussion: How clinical trials inform antibiotic stewardship Year: 2022